Funding is Essential for FDA Oncology Center of Excellence

By | September 5, 2017

In early 2017, the Oncology Center of Excellence (OCE) was established by the U.S. Food and Drug Administration (FDA) to modernize the cancer drug approval process by increasing intra-agency collaboration and promoting novel regulatory ideas and processes. Among critical, medical innovation initiatives, the 21st Century Cures Act (Cures) directed the Agency to create inter-center institutes in major disease areas that would accelerate FDA review by increasing agency interoperability.  With oncology products representing 30 percent of drugs approved by the FDA, the OCE was established as the first such inter-center institute. Led by Richard Pazdur, MD, often referred to by the media as the “Cancer Czar,” the OCE will employ an integrated approach to…

Click through to the AACR Cancer Policy Monitor to read the entire piece.

 

Leave a Reply

Your email address will not be published. Required fields are marked *